On November 12, 2019, Swedish Orphan Biovitrum AB (publ) completed the previously announced acquisition of Dova Pharmaceuticals, Inc., a Delaware corporation, pursuant to the Agreement and Plan of Merger, dated as of September 30, 2019, by and among Sobi, Dova and Dragonfly Acquisition Corp., a Delaware corporation and an indirect wholly owned subsidiary of Sobi. In connection with the Merger, each of Paul Manning, David Zaccardelli, Steven Goldman, Roger Jeffs, Alfred Novak, Sean Stalfort and Nancy Wysenski resigned as directors of the board of directors of Dova and from all committees of the Board on which such directors served, effective as of the Effective Time. In addition, effective as of the Effective Time, all of the Company's executive officers ceased to be officers of the Company and, effective as of November 12, 2019, each of David Zaccardelli, President and Chief Executive Officer, Mark W. Hahn, Chief Financial Officer, and Jason Hoitt, Chief Commercial Officer, separated from the Company.

Each of Messrs. Zaccardelli, Hahn and Hoitt is entitled to receive payments in accordance with the terms of the previously disclosed Company Officer Change in Control Severance Benefit Plan.